Page 19 - பல்கலைக்கழகம் மருத்துவமனை லெயிஸீக் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

th Annual Meeting of the EBMT   ZUG, Switzerland 15 March, 2021 bluebird bio, Inc. (Nasdaq: BLUE) announced new data from the clinical development programme for its investigational elivaldogene autotemcel (eli-cel, Lenti-D™) gene therapy in patients with cerebral adrenoleukodystrophy (CALD), including updated results from the pivotal Phase 2/3 Starbeam study (ALD-102) and the long-term follow-up study LTF-304, as well as safety outcomes from the Phase 3 ALD-104 study. These data were presented today in an oral presentation during the Presidential Symposium at the 47 th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2021), taking place virtually from March 14–17, 2021.   “The progression of CALD may occur rapidly, leading to severe neurological decline, and often death, of boys with this disease. The results presented today show that at 24 months of follow-up, 90% of patients (27/30) in our pivotal study of eli-cel (ALD-102) were ali

Richard colvinUniversity hospital leipzigVirtual congressMeeting of the european society for bloodPresents long term dataGene therapyCerebral adrenoleukodystrophyPresidential symposiumAnnual meetingEuropean societyMarrow transplantationPediatric oncologyUniversity hospitalUpdated resultsFirst reportSafety outcomes